Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.
When a person develops diabetes at a young age, is not overweight, and has several family members with the condition, is it really type 2 diabetes? In many cases, the answer may be no. A growing body of evidence suggests that thousands of people worldwide are living with HNF1A-MODY, a rare inherited form of diabetes that is frequently mistaken for either type 1 or type 2 diabetes. As a result, many patients receive treatments that may not be the best fit for their condition.
A recent clinical trial is reshaping how clinicians approach treatment for HNF1A-MODY. Researchers found that empagliflozin, an SGLT2 inhibitor commonly used to treat type 2 diabetes, may also provide meaningful glucose-lowering benefits for people living with HNF1A-MODY. The findings highlight the growing role of precision medicine and reinforce the importance of making the correct diagnosis before selecting therapy.
Table of Contents
- Understanding HNF1A-MODY
- Why It Is Often Misdiagnosed
- New Evidence for Empagliflozin
- What These Findings Mean for Clinical Practice
- Conclusion
- Frequently Asked Questions
Understanding HNF1A-MODY and Why It Is Different
HNF1A-MODY, also called MODY3, is the most common form of monogenic diabetes caused by mutations in the HNF1A gene. This gene plays a critical role in pancreatic beta-cell function. Unlike type 2 diabetes, insulin resistance is not the primary problem. Instead, patients gradually lose their ability to produce sufficient insulin because of impaired beta-cell function.
This inherited condition follows an autosomal dominant pattern, meaning multiple generations of the same family are often affected. However, because many patients initially respond to oral medications and do not fit the classic picture of type 1 diabetes, they are frequently labeled as having type 2 diabetes.
Several clinical clues should raise suspicion for MODY:
- Diabetes diagnosed before age 35
- Multiple generations with diabetes
- Absence of obesity or significant insulin resistance
- Detectable endogenous insulin production years after diagnosis
- Negative pancreatic autoantibodies
According to Diabetes In Control, recognizing atypical forms of diabetes is becoming increasingly important as more targeted therapies become available.
Genetic testing remains the gold standard for confirming HNF1A-MODY and distinguishing it from type 1 or type 2 diabetes. Unfortunately, many eligible patients are never tested, delaying optimal care for years or even decades.
Why Treatment for HNF1A-MODY Differs from Type 2 Diabetes
Choosing the most appropriate treatment for HNF1A-MODY begins with understanding the disease biology. Traditional type 2 diabetes therapies are often selected to improve insulin sensitivity. However, patients with HNF1A-MODY have relatively preserved insulin sensitivity but impaired insulin secretion.
For many years, low-dose sulfonylureas have been considered the preferred first-line therapy because individuals with HNF1A-MODY tend to be remarkably sensitive to these medications. In many cases, small doses produce excellent glycemic control.
However, sulfonylureas are not perfect. They increase the risk of hypoglycemia and may become less effective as beta-cell function declines over time. Consequently, clinicians have continued searching for additional treatment options that provide effective glucose control with fewer adverse effects.
That search has led investigators to evaluate newer diabetes medications, including SGLT2 inhibitors.
New Trial Suggests Empagliflozin May Expand Treatment Options for HNF1A-MODY
A recently published randomized crossover clinical trial evaluated empagliflozin in adults with genetically confirmed HNF1A-MODY. Researchers compared glucose-lowering responses with placebo while carefully monitoring safety and glycemic outcomes.
The results were encouraging.
Participants receiving empagliflozin experienced clinically meaningful improvements in blood glucose control. Because HNF1A mutations lower the kidney’s renal threshold for glucose, investigators had previously questioned whether SGLT2 inhibitors would provide sufficient benefit. Instead, the study demonstrated that empagliflozin continued to promote urinary glucose excretion while improving glycemic control.
Importantly, the treatment was generally well tolerated throughout the study period.
These findings suggest that empagliflozin could become another treatment option for patients with HNF1A-MODY, particularly for those who experience hypoglycemia with sulfonylureas or require combination therapy as their disease progresses.
Although larger and longer-term studies are still needed, this trial represents an important step toward more individualized diabetes care.
Additional information on MODY diagnosis and management is available from Diabetes UK.
Precision Medicine Is Changing Diabetes Care
The implications extend well beyond one medication. The study reinforces an important message for primary care physicians, endocrinologists, diabetes educators, and advanced practice providers: not every patient diagnosed with type 2 diabetes actually has type 2 diabetes.
An accurate genetic diagnosis influences medication selection, family screening, long-term prognosis, and overall diabetes management.
As genetic testing becomes more accessible and affordable, clinicians have greater opportunities to identify monogenic diabetes earlier. This allows patients to receive therapies specifically matched to the underlying cause of their disease rather than relying solely on conventional treatment algorithms.
Furthermore, identifying one patient with HNF1A-MODY often leads to testing and diagnosis of affected relatives who may also benefit from personalized treatment.
Healthcare providers should consider referral for genetic evaluation whenever a patient’s clinical presentation appears inconsistent with typical type 1 or type 2 diabetes. Earlier recognition can reduce unnecessary insulin use, improve glycemic outcomes, and enhance quality of life.
Patients seeking specialized diabetes evaluation can discuss genetic testing and individualized management with an endocrinologist through Healthcare.pro.
Conclusion
The latest clinical evidence suggests that empagliflozin may represent an important advancement in the treatment of HNF1A-MODY. While sulfonylureas remain a cornerstone of therapy, newer options could provide additional flexibility for patients requiring individualized management.
Perhaps the greatest lesson from this research is the importance of recognizing HNF1A-MODY in the first place. A patient who appears to have type 2 diabetes may actually have a genetically distinct condition requiring a very different treatment approach. As precision medicine continues to evolve, accurate diagnosis will become just as important as selecting the right medication.
Frequently Asked Questions
What is HNF1A-MODY?
HNF1A-MODY is a hereditary form of diabetes caused by mutations in the HNF1A gene that impair insulin production by pancreatic beta cells.
How is HNF1A-MODY different from type 2 diabetes?
Unlike type 2 diabetes, HNF1A-MODY is primarily caused by reduced insulin secretion rather than insulin resistance and typically runs strongly in families.
What is the standard treatment for HNF1A-MODY?
Low-dose sulfonylureas have traditionally been the preferred treatment because patients are highly sensitive to these medications.
Can empagliflozin be used for HNF1A-MODY?
New clinical trial data suggest empagliflozin may improve glucose control in adults with HNF1A-MODY, although additional studies are needed before widespread adoption.
When should clinicians suspect MODY?
MODY should be considered in patients diagnosed with diabetes at a young age, especially those with a strong family history, preserved insulin production, negative autoantibodies, and minimal insulin resistance.
Disclaimer: This content is for educational purposes only and is not intended as medical advice. Healthcare professionals should use clinical judgment and current guidelines when managing patients. Patients should consult their healthcare provider before making changes to their diabetes treatment. In an emergency, call 911 or your local emergency services.